BioNTech SE (BNTX) Free Cash Flow (2018 - 2025)
BioNTech SE (BNTX) posted Free Cash Flow of $433.8 million for Q4 2025, up 933.71% on a QoQ basis from $42.0 million in Q3 2025, and up 202.34% year-over-year from $143.5 million in Q4 2024.
BioNTech SE (BNTX) has 8 years of Free Cash Flow data on file, last reported at $433.8 million in Q4 2025.
- In Q4 2025, Free Cash Flow rose 202.34% year-over-year to $433.8 million; the TTM figure through Dec 2025 stood at -$263.3 million (down 121.53% YoY), while the FY2025 annual figure was $713.0 million, up 35.02% from the prior year.
- Free Cash Flow improved to $433.8 million in Q4 2025, from $42.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $4.9 billion in Q3 2022 and bottomed at -$769.8 million in Q1 2025.
- A 5-year average of $974.2 million and a median of $263.7 million in 2021 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 2701.2% — and 2023, when it slumped 1470.98%.
- Year by year, Free Cash Flow stood at -$183.1 million in 2021, then jumped by 638.01% to $985.4 million in 2022, then gained by 2.06% to $1.0 billion in 2023, then tumbled by 142.15% to -$423.9 million in 2024, then surged by 202.34% to $433.8 million in 2025.
- The last three Free Cash Flow figures came in at $433.8 million (Q4 2025), $42.0 million (Q3 2025), and $30.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn | 433.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 433.84 Mn |
| Dec 31, 2025 | 433.84 Mn |
| Sep 30, 2025 | 41.97 Mn |
| Sep 30, 2025 | 41.97 Mn |
| Jun 30, 2025 | 30.68 Mn |
| Jun 30, 2025 | 30.68 Mn |
| Mar 31, 2025 | -769.77 Mn |
| Mar 31, 2025 | -769.77 Mn |
| Dec 31, 2024 | -423.91 Mn |
| Dec 31, 2024 | -423.91 Mn |
| Sep 30, 2024 | 79.95 Mn |
| Sep 30, 2024 | 79.95 Mn |
| Jun 30, 2024 | 1.85 Bn |
| Jun 30, 2024 | 1.85 Bn |
| Mar 31, 2024 | -281.15 Mn |
| Mar 31, 2024 | -281.15 Mn |
| Dec 31, 2023 | 1.01 Bn |
| Dec 31, 2023 | 1.01 Bn |
| Sep 30, 2023 | 940.98 Mn |
| Sep 30, 2023 | 940.98 Mn |
| Jun 30, 2023 | 4.85 Bn |
| Jun 30, 2023 | 4.85 Bn |
| Mar 31, 2023 | -678.57 Mn |
| Mar 31, 2023 | -678.57 Mn |
| Dec 31, 2022 | 985.35 Mn |
| Dec 31, 2022 | 985.35 Mn |
| Sep 30, 2022 | 4.90 Bn |
| Sep 30, 2022 | 4.90 Bn |
| Jun 30, 2022 | 4.26 Bn |
| Jun 30, 2022 | 4.26 Bn |
| Mar 31, 2022 | 49.50 Mn |
| Mar 31, 2022 | 49.50 Mn |
| Dec 31, 2021 | -183.15 Mn |
| Dec 31, 2021 | -183.15 Mn |
| Sep 30, 2021 | 1.87 Bn |
| Sep 30, 2021 | 1.87 Bn |
| Jun 30, 2021 | 151.98 Mn |
| Jun 30, 2021 | 151.98 Mn |
| Mar 31, 2021 | 375.50 Mn |
| Mar 31, 2021 | 375.50 Mn |
| Dec 31, 2020 | -329.36 Mn |
| Dec 31, 2020 | -329.36 Mn |
| Sep 30, 2020 | 224.90 Mn |
| Sep 30, 2020 | 224.90 Mn |
| Jun 30, 2020 | 17.07 Mn |
| Jun 30, 2020 | 17.07 Mn |
| Mar 31, 2020 | 67.34 Mn |
| Mar 31, 2020 | 67.34 Mn |
| Dec 31, 2019 | -443.45 Mn |
| Dec 31, 2019 | -443.45 Mn |
| Sep 30, 2019 | 54.77 Mn |
| Sep 30, 2019 | 54.77 Mn |
| Jun 30, 2019 | 61.21 Mn |
| Jun 30, 2019 | 61.21 Mn |
| Mar 31, 2019 | 35.48 Mn |
| Mar 31, 2019 | 35.48 Mn |
| Dec 31, 2018 | -83.06 Mn |
| Dec 31, 2018 | -83.06 Mn |